DNase I plus -CTLA-4 combination therapy results in tumor growth inhibition, several CRs and enhanced survival in mice bearing CT26 or Colon26 MSS/MMRp CRC tumors. Dose response evaluations of DNase I ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...

The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can ...

Beyond Cancer announced key data demonstrating the efficacy of Low Volume Ultra-High Concentration Nitric Oxide, LV UNO, when combined with ...

Tsingke has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number of high-level academic papers published using Tsingke's products and services has ...

Researchers at the University of Michigan Rogel Cancer Center have discovered a key reason why some cancers do not respond to ...

Tsingke has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number of high-level academic papers published ...

Brenus Pharma has announced the publication of a scientific article describing its new "off-the-shelf" cancer treatment in ...

NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, today announced an ...

Pancreatic ductal adenocarcinoma (PDAC) is recognized as one of the most lethal cancers, with an estimated five-year survival ...